July 20, 2026
JB Hunt’s Best Quarter in Years
Record volumes, a 45% EPS jump, and a freight cycle turning in its favor.
First a note from Paradigm Press
Dear Reader,
He predicted the 2008 financial crisis…
He predicted Trump’s election in 2016….
He even predicted the rise of COVID-19 writing:
“The chance we don’t have something on the scale of a national pandemic in the next few years is near zero”
That was three months before the first reported case.
If he’s right again, God Bless America…
Because this crisis will be tectonic in scale…and it’s going to begin with the bubble popping in AI.
Click here to view his latest warning
Regards,
Matt Insley
Publisher, Paradigm Press
JB Hunt’s Best Quarter in Years
The results hit on July 15th. Shares jumped as much as 9.5% in after-hours trading. And honestly, the numbers earned it.
J.B. Hunt Transport Services (NASDAQ: JBHT) just posted its strongest quarter in years. Revenue up 19%. Operating income up 32%. Diluted EPS up 45% year over year, from $1.31 to $1.91. The company beat Wall Street’s estimate of $1.74 by a wide margin. Intermodal volumes set a quarterly record, surpassing 578,000 loads. That was the first double-digit volume growth quarter for the intermodal segment in over a decade.
Two years of grinding. Now the results are starting to show what that work was actually worth.
What Changed, and Why It Matters Now
Freight cycles are slow and then fast. JBHT spent most of 2023 and 2024 cutting costs, improving asset utilization, and waiting. The company removed over $135 million in structural costs during that stretch. The leaner operating model they built in the downturn is now meeting a recovering market. That combination is why operating income jumped 32% even as revenue climbed a relatively modest 19%.
The intermodal segment led the way. Revenue in that division climbed 22% to $1.75 billion, and operating income surged 58% to $150.9 million. Dedicated Contract Services revenue rose 9% to $921 million. Even the ICS brokerage arm, which lost $56 million in 2024, posted just $1.7 million in operating income this quarter, essentially at breakeven. Everything is moving in the same direction at once.
The debt picture also improved. Total debt declined to roughly $1.15 billion from $1.72 billion a year ago. The company repurchased about 392,000 shares for $98 million during the quarter, with $791 million still remaining under its buyback authorization.
The Truck Supply Story Nobody Is Watching Closely Enough
Here’s the thing that goes underappreciated in most JBHT coverage. The current freight tightening cycle is not being driven by a surge in consumer demand. It’s being driven by constrained supply.
On the trucking side, Class 8 orders have exploded in 2026 — up roughly 241% year over year in June alone, according to FTR Transportation Intelligence. But 2026 production slots are nearly full, and some demand is already spilling into 2027. Fleets are ordering aggressively now partly to get ahead of tougher EPA 2027 emissions standards, which are expected to raise equipment costs. Regulatory clarity, improving freight rates, and limited production capacity have converged at the same time.
What this means for JB Hunt’s intermodal segment is important. A 20% to 25% pricing gap between truckload and intermodal continues to push shippers toward rail-based solutions. When truck capacity is constrained and getting new equipment takes longer, that conversion accelerates. Intermodal wins when trucks are hard to get and expensive to run.
Slight tangent, but worth noting: driver supply is also tightening independently. New CDL rules, FMCSA enforcement actions, and driver school closures are all squeezing available capacity from the labor side. JBHT’s intermodal business doesn’t need drivers the same way a truckload carrier does. That’s a structural edge right now.
Your Complimentary Dividend Package
Today, you can claim the Ultimate Dividend Package… For FREE. (No credit card required!)
Inside, Marc Lichtenfeld – bestselling author of Get Rich with Dividends and world-renowned income expert – is giving away his top dividend picks for 2026.
You’ll get details on…
• Marc’s No. 1 dividend stock for 2026
• The safest 9% dividend in the world
• The top three “Extreme Dividend” stocks
• And much, much more!
The Business in Plain Terms
Five segments. Intermodal (JBI) moves freight on rail using JBHT-owned containers and chassis — cheaper and more fuel-efficient than over-the-road trucking on long hauls. Dedicated Contract Services (DCS) provides contracted fleet solutions directly to shippers. ICS is the brokerage arm. JBT handles truckload. Final Mile covers big-and-bulky home delivery.
The fixed-asset base is massive. JBI operates 124,838 pieces of company-owned trailing equipment, a chassis fleet of 104,474 units, 5,880 company-owned tractors, and 8,704 company drivers. You don’t replicate that infrastructure quickly. It’s a real moat.
CEO Shelley Simpson said on the earnings call that capacity has tightened across the industry, and attributed it to supply-side contraction rather than a broad pickup in demand. That’s actually the better kind of tightening for a company like JBHT, because it tends to be more durable. Demand-driven cycles reverse fast. Supply-driven ones take longer to unwind.
Key Numbers
- Q2 2026 Revenue: $3.50 billion, up 19% from $2.93 billion in Q2 2025
- Q2 2026 Operating Income: $259.5 million, up 32% year over year
- Q2 2026 Diluted EPS: $1.91, up 45% from $1.31 a year ago
- Q2 2026 Intermodal Revenue: $1.75 billion, up 22%; operating income up 58%
- Q2 2026 Intermodal Loads: Record 578,000-plus, up 10% year over year
- Full Year 2025 Revenue: $12.00 billion
- Full Year 2025 Net Earnings: $598 million, up 4.8%
- Debt Reduction: Down to ~$1.15 billion from $1.72 billion a year prior
- Structural Cost Removal: Over $135 million in the past year
- FY 2026 EPS Consensus: Analysts project approximately $7.27, up roughly 19% from $6.12 in 2025
Valuation: Where It Gets Complicated
JBHT is not cheap by classic value metrics. The trailing P/E sits around 44x, well above its 5-year median of roughly 27x. GuruFocus puts the stock at approximately 54% above its estimated intrinsic value. Morgan Stanley went as far as downgrading the stock to Underweight on July 6th, before earnings, with a $200 price target.
But the sell-side majority is still constructive. Benchmark raised its target to $300. Baird is at $290 with an Outperform. Raymond James moved to $299 with an Outperform. Susquehanna is at $326 with a Positive rating. Among 24 analysts tracked by Stock Analysis, the consensus is Buy with an average 12-month price target of $288.18. The high is $330.
So the debate is real. You have a franchise in the early innings of a freight cycle recovery, with earnings momentum accelerating, trading at a premium multiple. That’s not unusual at cycle turns. Growth investors love it. Value investors wince at it.
The honest framing: this is not a distressed asset play. It’s a quality compounder at a cycle-recovery premium. Those have a habit of staying expensive longer than anyone expects if the earnings keep coming.
Three Paths From Here
Optimistic path: Supply-side tightening holds through 2026 and into 2027. EPA-driven equipment cost increases push more shippers toward intermodal. Intermodal pricing improves meaningfully in the next contract bid cycle. DCS adds net trucks again. Full-year 2026 EPS lands at or above $7.27. The multiple compresses gradually as earnings grow into the valuation.
Middle path: Volumes stay firm, pricing recovery is gradual. Cost discipline holds. Margin expansion continues at a modest pace. EPS grows steadily but does not blow out estimates. The stock trades sideways to slightly higher.
Cautious path: 2026 production slots fill quickly and new trucks hit the road faster than expected in 2027, easing capacity and pressuring rates. Macro softness hits consumer freight demand. The Final Mile segment faces continued headwinds from lost appliance business. The premium multiple becomes harder to defend.
The Biggest Unsolved Problem in Medicine?
Over half a billion people battle osteoarthritis* in a $560B market with no cure. Thankfully, Cytonics may have cracked the code.
They discovered the body already produces a naturally occurring protein that helps protect cartilage, just not enough where it’s needed most. So they developed a therapy that has already been used in more than 10,000 patients, and are now advancing a version that’s 200% more potent toward FDA approval.
If approved, it would be the first therapy to halt cartilage destruction and promote regrowth.
Invest in Cytonics before this month’s deadline.
*Source: The Lancet Rheumatology
This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://cytonics.com/
Forward-looking statements are subject to risks and uncertainties. There is no guarantee of performance. Past performance does not predict future results. All investments involve risk, including loss of principal.
Here’s where I land on this. The Q2 results were genuinely strong, not just strong relative to low expectations. Record intermodal loads. Debt coming down hard. Costs structurally lower than a year ago. And an industry backdrop where new truck supply is constrained and driver availability is shrinking. JB Hunt is built for exactly this kind of environment.
The valuation is the honest asterisk. At these prices you’re paying for a recovery that is now well underway, not one that’s still speculative. For aggressive investors, that might still be fine if earnings keep accelerating. For value-focused investors, patience and a lower entry point makes sense.
Watch the intermodal pricing trend into the 2027 bid season. That’s the next real data point. If pricing inflects higher on top of the volume gains, the bull case gets a lot louder.
The Cheap Investor
